Figure 2 4.1 Imaging of Gln metabolism predicts treatment response Abnormal Gln metabolism has facilitated the use of non-invasive imaging techniques for early tumor diagnosis and treatment monitoring, such as 18F-(2S,4R)-4-fluoroglutamine (18F-FGln) PET and L-(71)
Participants in trials undergo regular monitoring of weight, blood glucose, HbA1c, lipid profile, liver and renal function, and cardiovascular parameters
Treatment discontinuation due to side effects occurred in 4.1% of participants receiving 4 mg, 6.9% receiving 9 mg, and 11.3% receiving 12 mg, compared with 4.9% in the placebo group
Boeckx, R.L
For many years, we have been supplying customers throughout Germany and across numerous European Union countries with high-quality medicines, natural remedies, and healthcare products